AI Terminal
Median Technologies
Declaration of Voting Results & Voting Rights Announcements • Dec 3, 2025
1514_dva_2025-12-03_84e22bcf-43f0-4e40-a7a0-f17e9c065847.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Press release – For immediate release December 3, 2025 – 5:45 pm CET
Disclosure of total number of voting rights and number of shares in the capital as of November 30, 2025
Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations.
Sophia Antipolis, France
| Total number of shares | 36,741,587 |
|---|---|
| Number of real voting rights (excluding treasury shares*) |
36,669,667 |
| Theoretical number of voting rights (including treasury shares*) |
36,718,387 |
(*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S.
and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Contacts
Median Technologies
Emmanuelle Leygues VP, Corporate Marketing & Financial Communications +33 6 10 93 58 88 [email protected]
Investors - ACTIFIN Ghislaine Gasparetto +33 6 85 36 76 81 [email protected]
Press – Ulysse Communication
Bruno Arabian +33 6 87 88 47 26 [email protected] Nicolas Entz +33 6 33 67 31 54 [email protected]